MAPT and Alzheimer disease: Formal AD diagnosis is now strengthened by the use of biomarkers (analysis of amyloid and tau protein in the cerebrospinal fluid and/or amyloid positron emission tomography), even if it can only be confirmed by postmortem brain autopsy [91, 92]; none of which were available for the study.